193 related articles for article (PubMed ID: 18088157)
1. Carmustine implants for the treatment of newly diagnosed high-grade gliomas: a cost-utility analysis.
Rogers G; Garside R; Mealing S; Pitt M; Anderson R; Dyer M; Stein K; Somerville M
Pharmacoeconomics; 2008; 26(1):33-44. PubMed ID: 18088157
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
3. A pilot cost-effectiveness analysis of treatments in newly diagnosed high-grade gliomas: the example of 5-aminolevulinic Acid compared with white-light surgery.
Esteves S; Alves M; Castel-Branco M; Stummer W
Neurosurgery; 2015 May; 76(5):552-62; discussion 562. PubMed ID: 25714513
[TBL] [Abstract][Full Text] [Related]
4. Incorporating BCNU wafers into malignant glioma treatment: European case studies.
Balossier A; Dörner L; Emery E; Heese O; Mehdorn HM; Menei P; Singh J
Clin Drug Investig; 2010; 30(3):195-204. PubMed ID: 20155992
[TBL] [Abstract][Full Text] [Related]
5. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
Westphal M; Hilt DC; Bortey E; Delavault P; Olivares R; Warnke PC; Whittle IR; Jääskeläinen J; Ram Z
Neuro Oncol; 2003 Apr; 5(2):79-88. PubMed ID: 12672279
[TBL] [Abstract][Full Text] [Related]
6. Risk management in the treatment of malignant gliomas with BCNU wafer implants.
Giese A; Bock HC; Kantelhardt SR; Rohde V
Cent Eur Neurosurg; 2010 Nov; 71(4):199-206. PubMed ID: 20063259
[TBL] [Abstract][Full Text] [Related]
7. [Risk Factors for Adverse Events after Implantation of BCNU Wafers in High-grade Gliomas].
Yoshida M; Yamaguchi S; Ishi Y; Endo S; Motegi H; Kobayashi H; Asaoka K; Kamoshima Y; Terasaka S; Houkin K
No Shinkei Geka; 2015 Jul; 43(7):603-10. PubMed ID: 26136324
[TBL] [Abstract][Full Text] [Related]
8. Localized BCNU chemotherapy and the multimodal management of malignant glioma.
La Rocca RV; Mehdorn HM
Curr Med Res Opin; 2009 Jan; 25(1):149-60. PubMed ID: 19210148
[TBL] [Abstract][Full Text] [Related]
9. Carmustine wafer implantation when surgical cavity is communicating with cerebral ventricles: technical considerations on a clinical series.
Della Puppa A; Rossetto M; Ciccarino P; Denaro L; Rotilio A; d'Avella D; Scienza R
World Neurosurg; 2011; 76(1-2):156-9; discussion 67-8. PubMed ID: 21839967
[TBL] [Abstract][Full Text] [Related]
10. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.
Pan E; Mitchell SB; Tsai JS
J Neurooncol; 2008 Jul; 88(3):353-7. PubMed ID: 18389176
[TBL] [Abstract][Full Text] [Related]
11. Importance and accuracy of intraoperative frozen section diagnosis of the resection margin for effective carmustine wafer implantation.
Asano K; Kurose A; Kamataki A; Kato N; Ogawa K; Katayama K; Kakuta K; Fumoto T; Ohkuma H
Brain Tumor Pathol; 2018 Jul; 35(3):131-140. PubMed ID: 29948295
[TBL] [Abstract][Full Text] [Related]
12. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine.
Selker RG; Shapiro WR; Burger P; Blackwood MS; Arena VC; Gilder JC; Malkin MG; Mealey JJ; Neal JH; Olson J; Robertson JT; Barnett GH; Bloomfield S; Albright R; Hochberg FH; Hiesiger E; Green S;
Neurosurgery; 2002 Aug; 51(2):343-55; discussion 355-7. PubMed ID: 12182772
[TBL] [Abstract][Full Text] [Related]
13. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.
Buckner JC; Schomberg PJ; McGinnis WL; Cascino TL; Scheithauer BW; O'Fallon JR; Morton RF; Kuross SA; Mailliard JA; Hatfield AK; Cole JT; Steen PD; Bernath AM
Cancer; 2001 Jul; 92(2):420-33. PubMed ID: 11466698
[TBL] [Abstract][Full Text] [Related]
14. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Recinos VR; Tyler BM; Bekelis K; Sunshine SB; Vellimana A; Li KW; Brem H
Neurosurgery; 2010 Mar; 66(3):530-7; discussion 537. PubMed ID: 20173548
[TBL] [Abstract][Full Text] [Related]
15. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
Catalán-Uribarrena G; Bilbao-Barandica G; Pomposo-Gaztelu I; Undabeitia-Huertas J; Ruiz de Gopegui-Ruiz E; Galbarriatu-Gutiérrez L; Canales-Llantada M; Aurrecoechea-Obieta J; Igartua-Azkune A; Carbayo-Lozano G
Acta Neurochir (Wien); 2012 Feb; 154(2):211-22; discussion 222. PubMed ID: 22002506
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma.
Qian Y; Maruyama S; Kim H; Pollom EL; Kumar KA; Chin AL; Harris JP; Chang DT; Pitt A; Bendavid E; Owens DK; Durkee BY; Soltys SG
Neuro Oncol; 2017 Nov; 19(12):1651-1660. PubMed ID: 28666368
[TBL] [Abstract][Full Text] [Related]
18. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience.
Sabel M; Giese A
Curr Med Res Opin; 2008 Nov; 24(11):3239-57. PubMed ID: 18940042
[TBL] [Abstract][Full Text] [Related]
19. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
20. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
